Related Experiment Video
Updated: Aug 11, 2026
08:15
Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
Published on: May 10, 2024
Hypoglycemic activity of jatrorrhizine
Yan Fu1, Benrong Hu, Qiang Tang
1Department of Pharmacology, School of Basic Medical Sciences, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Summary
Jatrorrhizine (Jat) effectively lowers blood glucose in normal and diabetic mice by enhancing aerobic glycolysis. This natural compound also reduces liver glycogen and inhibits platelet aggregation.
Area of Science:
- Pharmacology
- Biochemistry
- Metabolic Research
Background:
- Jatrorrhizine (Jat) is a compound with potential therapeutic applications.
- Understanding the mechanism of action for hypoglycemic agents is crucial for diabetes management.
Purpose of the Study:
- To investigate the hypoglycemic activity of Jatrorrhizine (Jat).
- To elucidate the underlying mechanism of Jat's glucose-lowering effects, focusing on glycolysis pathways.
Main Methods:
- Assessed blood glucose and liver glycogen levels using spectrophotometry.
- Measured blood lactic acid (LC) and liver lactate dehydrogenase (LDH) activity for anaerobic glycolysis assessment.
- Determined liver succinate dehydrogenase (SDH) activity to evaluate aerobic glycolysis.
- Investigated in vitro platelet aggregation in rabbits.
Main Results:
- Jat significantly reduced blood glucose in normal and alloxan-induced hyperglycemic mice in a dose- and time-dependent manner.
- Jat increased liver succinate dehydrogenase (SDH) activity, indicating enhanced aerobic glycolysis.
- Jat had no significant effect on blood lactic acid (LC) or liver lactate dehydrogenase (LDH) activity.
- Jat reduced liver glycogen content in normal mice and inhibited platelet aggregation in rabbits.
Conclusions:
- Jatrorrhizine exhibits significant hypoglycemic activity in both normal and hyperglycemic models.
- The primary mechanism for Jat's hypoglycemic effect appears to be the enhancement of aerobic glycolysis.
- Jat may also influence glycogen metabolism and possess anti-platelet aggregation properties.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...